Cited 1 times in
Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경환 | - |
dc.contributor.author | 김은영 | - |
dc.contributor.author | 박병조 | - |
dc.contributor.author | 변화경 | - |
dc.contributor.author | 윤홍인 | - |
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 이창걸 | - |
dc.contributor.author | 이창영 | - |
dc.contributor.author | 조재호 | - |
dc.contributor.author | 홍민희 | - |
dc.contributor.author | 양고운 | - |
dc.date.accessioned | 2023-05-31T05:30:34Z | - |
dc.date.available | 2023-05-31T05:30:34Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194204 | - |
dc.description.abstract | Introduction: We aimed to identify the role of radiotherapy (RT) in the treatment of thymic carcinoma as well as the optimal RT target volume. Materials and Methods: This single-institution retrospective study included 116 patients diagnosed with thymic carcinoma between November 2006 and December 2021 who received multimodal treatment including RT with or without surgery or chemotherapy. Seventy-nine patients (68.1%) were treated with postoperative RT, 17 patients (14.7%) with preoperative RT, 11 patients (9.5%) with definitive RT, and nine patients (7.8%) with palliative RT. The target volume was defined as the tumor bed or gross tumor with margin, and selective irradiation of the regional nodal area was performed when involved. Results: With a median follow-up of 37.0 (range, 6.7–174.3) months, the 5-year overall survival (OS), progression-free survival, and local recurrence-free survival rates were 75.2%, 47.7% and 94.7%, respectively. The 5-year OS was 51.9% in patients with unresectable disease. Overall, 53 recurrences were observed, of which distant metastasis was the most common pattern of failure (n = 32, 60.4%) after RT. No isolated infield or marginal failures were observed. Thirty patients (25.8%) who had lymph node metastases at the initial diagnosis had regional nodal areas irradiated. There was no lymph node failure inside the RT field. A tumor dimension of ≥5.7 cm (hazard ratio [HR] 3.01; 95% confidence interval [CI] 1.25–7.26; p = 0.030) and postoperative RT (HR 0.20; 95% CI 0.08–0.52; p = 0.001) were independently associated with OS. Intensity-modulated-RT-treated patients developed less overall toxicity (p < 0.001) and esophagitis (p < 0.021) than three-dimensional-conformal-RT-treated patients. Conclusions: A high local control rate was achieved with RT in the primary tumor sites and involved lymph node area in the treatment of thymic carcinoma. A target volume confined to the tumor bed or gross tumor plus margin with the involved lymph node stations seems reasonable. The advanced RT techniques with intensity-modulated RT have led to reduced RT-related toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Gowoon Yang | - |
dc.contributor.googleauthor | Chang Young Lee | - |
dc.contributor.googleauthor | Eun Young Kim | - |
dc.contributor.googleauthor | Chang Geol Lee | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Byung Jo Park | - |
dc.contributor.googleauthor | Hong In Yoon | - |
dc.contributor.googleauthor | Kyung Hwan Kim | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Hwa Kyung Byun | - |
dc.contributor.googleauthor | Jaeho Cho | - |
dc.identifier.doi | 10.3390/cancers15082262 | - |
dc.contributor.localId | A05226 | - |
dc.contributor.localId | A00811 | - |
dc.contributor.localId | A06090 | - |
dc.contributor.localId | A05136 | - |
dc.contributor.localId | A04777 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A03240 | - |
dc.contributor.localId | A03245 | - |
dc.contributor.localId | A03901 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 37190190 | - |
dc.subject.keyword | combined modality therapy | - |
dc.subject.keyword | radiotherapy | - |
dc.subject.keyword | survival rate | - |
dc.subject.keyword | thymus neoplasms | - |
dc.contributor.alternativeName | Kim, Kyung Hwan | - |
dc.contributor.affiliatedAuthor | 김경환 | - |
dc.contributor.affiliatedAuthor | 김은영 | - |
dc.contributor.affiliatedAuthor | 박병조 | - |
dc.contributor.affiliatedAuthor | 변화경 | - |
dc.contributor.affiliatedAuthor | 윤홍인 | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 이창걸 | - |
dc.contributor.affiliatedAuthor | 이창영 | - |
dc.contributor.affiliatedAuthor | 조재호 | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2262 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.15(8) : 2262, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.